Samsung Bioepis

(Image: Getty/Evgeny_D)

FDA approves the entrance of two biosimilars

By Ben Hargreaves

US FDA gives approval to Samsung Bioepis’ Humira biosimilar and Pfizer’s Rituxan biosimilar, as the number of such medicines gaining entry onto the US market steadily increases.

(Image: Getty/Motortion)

UPDATED

Questions mount over Samsung accounting case

By Maggie Lynch

An executive at Samsung is issued an arrest warrant, as prosecutors in South Korea continue to look into the accounting case leading up the IPO of Samsung BioLogics.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers